Abstract
ObjectiveTo assess the impact of post-covid-19 conditions among adults.DesignSystematic review and meta-analysis of health outcomes in controlled studies.Data sourcesTwo sources were searched from database inception to 20 October 2022: Cochrane covid‐19 study register (comprising Cochrane Central Register of Controlled Trials, Medline, Embase, clinicalTrials.gov, World Health Organization's International Clinical Trials Registry Platform, medRxiv) and WHO's covid-19 research database.Eligibility criteriaCohort studies recruiting more than 100 participants with a control group and a follow-up of at least 12 weeks were included. Adults who were documented to have SARS-CoV-2 infection based on clinical, imaging, or laboratory criteria were included.Data extraction and synthesisTwo independent reviewers extracted data. The main outcomes included quality of life, functionality in daily activities, use of resources, recovery rates (cluster of symptoms), and the incidence of new medical diagnoses. Data were pooled using a random effects model. The risk of bias was assessed with the Joanna Briggs Institute critical appraisal tool for cohort studies.ResultsWe included 63 controlled cohort studies, encompassing more than 96 million participants. Based on five studies, we found a reduction in overall quality of life between individuals with confirmed SARS-CoV-2 infection versus controls at six to 24 months follow-up, although heterogeneity was very high (mean difference in EQ-5D scale −5.28 (95% confidence interval −7.88 to 2.68; I2=93.81%). Evidence from ten studies, which could not be pooled in a meta-analysis, indicated that an increased rate of functional impairment associated with SARS-CoV-2 infection. Use of care increased compared with controls at six to 24 months follow-up at intensive care units (risk ratio 2.00 (95% confidence interval 0.69 to 5.80), five studies, I2=91.96%) and in outpatient care (1.12 (1.01 to 1.24), seven studies, I2=99.51%). Regarding persistent symptoms, individuals with documented SARS-CoV-2 infection had an increased risk of having two or more persistent symptoms at follow-up, especially those related to neurological clusters (ie, risk ratio 1.51 (95% confidence interval 1.17 to 1.93), I2=98.91%). Evidence also showed an increased incidence of a wide variety of metabolic, cardiovascular, neurological, respiratory, haematological and other incident diagnoses.ConclusionEvidence suggests functional impairment after SARS-CoV-2 infection, in addition to a higher use of resources and a higher incidence of widely varying medical diagnoses. These results should be interpreted with caution, considering the high heterogeneity across studies and study limitations related to outcome measurement and attrition of participants.Systematic review registrationOpen Science Framework,osf.io/drm39
Funder
Robert Koch Institut, Germany
Reference64 articles.
1. S1-Leitlinie Post-COVID/Long-COVID
2. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline
3. A clinical case definition of post COVID-19 condition by A Delphi consensus, 6 October . 2021 Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 [Accessed 1 Sep 2022].
4. RKI - . Coronavirus SARS-CoV-2 - Scoping Review und Evidence Maps zu Long COVID, Available: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Long-COVID/Scoping-Review.html [Accessed 1 Sep 2022].
5. Franco JVA , Garegnani LI , Oltra GV , et al . Long-term health symptoms and sequelae following SARS-Cov-2 infection: an evidence map. Int J Environ Res Public Health 2022;19. doi:10.3390/ijerph19169915
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献